Losmapimod Did Not Benefit Patients with Facioscapulohumeral Muscular Dystrophy | Docwire News
Losmapimod failed to show clinical benefit over placebo in FSHD patients in the phase 3 REACH trial, ending its development.
Related Articles
Treatment Effects on Acute and Chronic GFR Slope in Clinical Trials | Docwire News
An analysis of chronic kidney disease (CKD) trials supported 3-year total slope as the primary slope-based outcome in randomized trials.
Targeting IDH1 Mutations: Olutasidenib Trial Begins in Higher-Risk MDS Patients | Docwire News
The study will assess the overall response to olutasidenib plus azacitidine in higher-risk MDS, CMML, and advanced MPNs.
Researchers Identify Environmental Risk Factors for IgAN and MN | Docwire News
Several genetically predicted environmental factors increase the risk of IgA nephropathy (IgAN) and membranous nephropathy (MN), a study found.
Minimizing Glucocorticoid Use in Patients With ANCA-Associated Vasculitis | Docwire News
A study found that combination cyclophosphamide and rituximab therapy for severe ANCA-associated vasculitis to minimize glucocorticoid use may reduce morbidity.
Iron Deficiency Anemia Correlated With Increased Likelihood of Ischemic Stroke | Docwire News
Iron deficiency anemia was associated with 39% increased odds of stroke, independent of the risk factors for stroke.
Proteinuria Trajectory Predicts Progression of IgA Nephropathy | Docwire News
Proteinuria trajectory is a major predictor of disease progression in children and adults with IgA nephropathy (IgAN), a study found.
Combo Therapy That Slashes UACR Could Be a Game Changer for CKD | Docwire News
Rajiv Agarwal, MBBS, discussed a study showing that a finerenone and empagliflozin combination has superior efficacy at reducing UACR in chronic kidney disease and type…
Enhanced Belimumab Results in BLISS-LN Subgroup Analysis | Docwire News
Dr. Richard Furie spoke with Nephrology Times about new data from the BLISS-LN study supporting the efficacy and safety of belimumab for active proliferative lupus…
Study Identifies microRNA-483-5p as Potential Biomarker for IgAN Progression | Docwire News
Research identified microRNA-483-5p as a possible biomarker for IgA nephropathy (IgAN) to help with risk stratification.